K. Kikkawa

发表

Novel, potent, and selective phosphodiesterase 5 inhibitors: synthesis and biological activities of a series of 4-aryl-1-isoquinolinone derivatives.

J. Kotera, K. Omori, T. Ukita, 2001, Journal of medicinal chemistry.

T-1032, a novel specific phosphodiesterase type 5 inhibitor, increases venous compliance in anesthetized rats.

H. Inoue, K. Kikkawa, K. Yano, 2001, European journal of pharmacology.

Characteristics of heterogeneity in the expression of vasoconstriction in response to N(G)-monomethyl-L-arginine in isolated canine arteries.

K. Kikkawa, T. Hoshino, S. Murata, 1999, European journal of pharmacology.

Pharmacological profile of T-0201, a highly potent and orally active endothelin receptor antagonist.

K. Kikkawa, T. Hoshino, H. Yabana, 1998, The Journal of pharmacology and experimental therapeutics.

[Antihypertensive drugs in clinical development].

K. Kikkawa, 2006, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum.

H. Inoue, M. Takagi, K. Kikkawa, 2001, European journal of pharmacology.

Enzymological and pharmacological profile of T-0156, a potent and selective phosphodiesterase type 5 inhibitor.

H. Inoue, K. Fujishige, J. Kotera, 2002, European journal of pharmacology.

Acute and chronic effects of T-1032, a novel selective phosphodiesterase type 5 inhibitor, on monocrotaline-induced pulmonary hypertension in rats.

H. Inoue, M. Takagi, K. Kikkawa, 2002, Biological & pharmaceutical bulletin.

Modifications and structure-activity relationships at the 2-position of 4-sulfonamidopyrimidine derivatives as potent endothelin antagonists.

K. Kikkawa, Koichiro Yamada, H. Morimoto, 2002, Bioorganic & medicinal chemistry letters.

Design, syntheses, and structure-activity relationships of indan derivatives as endothelin antagonists; new lead generation of non-peptidic antagonist from peptidic leads.

K. Kikkawa, C. Fukushima, H. Morimoto, 2001, Bioorganic & medicinal chemistry.

Cloning of hamster preproendothelin-1 cDNA and its expression in the heart.

Y. Sugishita, K. Kikkawa, T. Miyauchi, 1998, Journal of cardiovascular pharmacology.

Role of adenosine and P2 receptors in the penile tumescence in anesthetized dogs.

H. Inoue, K. Kikkawa, T. Noto, 2001, European journal of pharmacology.

Endothelium‐dependent calcium‐induced relaxation in the presence of Ca2+ ‐antagonists in canine depolarized coronary arteries

T. Nagao, K. Kikkawa, S. Murata, 1989, British journal of pharmacology.

Prevention of cerebral vasospasm by a novel endothelin receptor antagonist, TA-0201.

K. Kikkawa, H. Iwasaki, T. Hoshino, 1999, Journal of cardiovascular pharmacology.

Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.

J. Kotera, K. Omori, A. Burnett, 2012, The journal of sexual medicine.

Cerebral vasodilating and spasmolytic actions of a new Ca-antagonist, clentiazem (TA-3090), in anesthetized animals.

T. Nagao, K. Kikkawa, S. Murata, 1992, Journal of cardiovascular pharmacology.

The Discovery of Stendra™(Avanafil) for the Treatment of Erectile Dysfunction

K. Omori, K. Kikkawa, Koichiro Yamada, 2015 .

Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist.

K. Takedomi, Y. Yamamoto, K. Kikkawa, 2022, Journal of medicinal chemistry.

[Revisiting the therapeutic concept of a mineralocorticoid receptor antagonist - focusing on resistant hypertension and chronic renal failure].

K. Kikkawa, 2012, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

T-1032, a novel phosphodiesterase type 5 inhibitor, increases the survival of cardiomyopathic hamsters.

H. Inoue, M. Takagi, K. Kikkawa, 2002, European journal of pharmacology.

Calcium antagonistic and spasmolytic activities of a new 1,5-benzothiazepine derivative in isolated canine and monkey arteries.

T. Nagao, K. Kikkawa, S. Murata, 1988, Arzneimittel-Forschung.

Cardiovascular effects of a new 1,5-benzothiazepine calcium antagonist in anesthetized dogs.

T. Nagao, K. Kikkawa, H. Yabana, 1988, Arzneimittel-Forschung.

1,7- and 2,7-naphthyridine derivatives as potent and highly specific PDE5 inhibitors.

K. Fujishige, J. Kotera, K. Omori, 2003, Bioorganic & medicinal chemistry letters.

Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction.

H. Inoue, K. Fujishige, J. Kotera, 2012, The Journal of urology.

Potentiation of penile tumescence by T-1032, a new potent and specific phosphodiesterase type V inhibitor, in dogs.

H. Inoue, K. Kikkawa, T. Ikeo, 2000, The Journal of pharmacology and experimental therapeutics.

T-0156, a novel phosphodiesterase type 5 inhibitor, and sildenafil have different pharmacological effects on penile tumescence and electroretinogram in dogs.

H. Inoue, K. Kikkawa, K. Yano, 2004, European journal of pharmacology.

The discovery of avanafil for the treatment of erectile dysfunction: a novel pyrimidine-5-carboxamide derivative as a potent and highly selective phosphodiesterase 5 inhibitor.

K. Fujishige, J. Kotera, K. Omori, 2014, Bioorganic & medicinal chemistry letters.

Long-lasting hypotensive and antihypertensive effects of a new 1,5-benzothiazepine calcium antagonist in hypertensive rats and renal hypertensive dogs.

T. Nagao, K. Kikkawa, H. Narita, 1988, Arzneimittel-Forschung.

Avanafil, a highly selective phosphodiesterase type 5 inhibitor for erectile dysfunction, shows good safety profiles for retinal function and hemodynamics in anesthetized dogs.

H. Inoue, K. Kikkawa, K. Yano, 2013, The Journal of urology.

Effects of Clentiazem on Cerebral Ischemia Induced by Carotid Artery Occlusion in Stroke-Prone Spontaneously Hypertensive Rats

T. Nagao, K. Kikkawa, T. Tetsuka, 2005 .

Sildenafil and T-1032, phosphodiesterase type 5 inhibitors, showed a different vasorelaxant property in the isolated rat aorta.

H. Inoue, M. Takagi, K. Kikkawa, 2002, European journal of pharmacology.

8-(3-chloro-4-methoxybenzyl)-8H-pyrido[2,3-d]pyrimidin-7-one derivatives as potent and selective phosphodiesterase 5 inhibitors.

K. Fujishige, J. Kotera, K. Omori, 2015, Bioorganic & medicinal chemistry letters.

Design and synthesis of novel 5-(3,4,5-trimethoxybenzoyl)-4-aminopyrimidine derivatives as potent and selective phosphodiesterase 5 inhibitors: scaffold hopping using a pseudo-ring by intramolecular hydrogen bond formation.

K. Fujishige, J. Kotera, K. Omori, 2014, Bioorganic & medicinal chemistry letters.

Synthesis of the optically active trans-isomers of diltiazem and their cardiovascular effects and Ca-antagonistic activity.

H. Inoue, T. Yamaguchi, K. Kikkawa, 1992, Chemical & pharmaceutical bulletin.

Synthesis of the Optically Active trans‐Isomers of Diltiazem and Their Cardiovascular Effects and Ca‐Antagonistic Activity.

Takashi Tanaka, T. Nagao, K. Kikkawa, 1993 .